GERMANY – Mainz Biomed N.V., a molecular genetics diagnostic company focused on cancer detection, has entered into a strategic collaboration with Thermo Fisher Scientific Inc., a global leader in life sciences solutions.
This partnership aims to accelerate the development and potential commercialization of Mainz Biomed’s next-generation colorectal cancer (CRC) screening test, leveraging cutting-edge mRNA-based technology.
The collaboration will combine Mainz Biomed’s innovative approach to early cancer detection with Thermo Fisher’s extensive expertise in advanced technologies, instrumentation, and information systems.
Together, the companies aim to redefine the standards for non-invasive CRC screening by improving the detection of colorectal cancer and precancerous lesions, particularly advanced adenomas.
A strategic advancement in cancer screening
Mainz Biomed’s flagship product, ColoAlert®, is a non-invasive diagnostic test for CRC that has already shown strong clinical performance in both U.S. and European trials.
The test’s focus on identifying advanced adenomas — precancerous lesions that significantly increase the risk of developing CRC — sets it apart in the competitive screening market.
Thermo Fisher’s extensive resources and global infrastructure will enhance Mainz Biomed’s ability to develop proprietary assays and scale its next-generation CRC screening test.
This collaboration also validates Mainz Biomed’s technology, potentially opening doors to further partnerships and investment opportunities.
Guido Baechler, CEO of Mainz Biomed, emphasized the importance of this collaboration:
“This partnership with Thermo Fisher will be instrumental to our goal of bringing to market a home collection colorectal screening tool with highly effective detection of adenomas.
Thermo Fisher’s scalable, class-leading technologies will significantly enhance our product development, accelerating the availability of an innovative test for colorectal cancer screening worldwide.”
Strengthening Market Potential
The global CRC screening market is projected to reach US $1.2 billion by 2025, and this partnership positions Mainz Biomed to capture a substantial share.
The collaboration offers Mainz access to Thermo Fisher’s established distribution channels and world-class technological infrastructure, enabling accelerated product development and global reach.
Peter Jacobs, Director of EMEA Clinical Business Development at Thermo Fisher Scientific, shared his optimism:
“We are excited at the prospect of working with Mainz Biomed on their next-generation screening test. Together, we are confident in achieving rapid progress and delivering innovative new assays to the global clinical marketplace.”
For Mainz Biomed, a small-cap company with a market capitalization of US $5.6 million, this partnership significantly reduces risks in its development pathway.
By aligning with an industry giant like Thermo Fisher (market cap over US $200 billion), Mainz gains access to critical resources that enhance its ability to scale and commercialize its products.
Driving innovation with cutting-edge solutions
The CRC screening market is evolving rapidly, driven by advancements in technology and growing consumer demand for at-home diagnostic solutions.
Mainz Biomed’s next-generation test aligns with these trends, offering convenience without compromising accuracy.
By focusing on detecting adenomas, the test addresses a critical unmet need, potentially differentiating it from competitors.
Additionally, Mainz’s portfolio includes PancAlert, an early-stage pancreatic cancer screening test.
This pipeline of innovative diagnostics further positions the company as a leader in molecular genetic solutions for life-threatening diseases.
Why this matters
Colorectal cancer remains a leading cause of cancer-related deaths worldwide, yet it is highly treatable when detected early.
Innovations like Mainz Biomed’s mRNA-based screening tests offer hope for more effective and accessible diagnostics, ultimately saving lives and reducing healthcare costs.
